​

Lifecore Biomedical (LFCR) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

LFCR Stock Forecast

Lifecore Biomedical stock forecast is as follows: an average price target of $6.50 (represents a -10.22% downside from LFCR’s last price of $7.24) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

LFCR Price Target

The average price target for Lifecore Biomedical (LFCR) is $6.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.00. This represents a potential -10.22% downside from LFCR's last price of $7.24.

LFCR Analyst Ratings

Buy

According to 2 Wall Street analysts, Lifecore Biomedical's rating consensus is 'Buy'. The analyst rating breakdown for LFCR stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Lifecore Biomedical Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 04, 2024Jacob JohnsonStephens$5.00$5.38-7.06%-30.94%
Sep 05, 2024Matthew HewittCraig-Hallum$8.00$4.2289.57%10.50%

The latest Lifecore Biomedical stock forecast, released on Oct 04, 2024 by Jacob Johnson from Stephens, set a price target of $5.00, which represents a -7.06% decrease from the stock price at the time of the forecast ($5.38), and a -30.94% decrease from LFCR last price ($7.24).

Lifecore Biomedical Price Target by Period

1M3M12M
# Anlaysts-12
Avg Price Target-$5.00$6.50
Last Closing Price$7.24$7.24$7.24
Upside/Downside-100.00%-30.94%-10.22%

In the current month, the average price target of Lifecore Biomedical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lifecore Biomedical's last price of $7.24. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 22, 2024Craig-HallumBuyBuyHold
Oct 04, 2024StephensEqual-WeightEqual-WeightHold
Sep 05, 2024Craig-HallumBuyInitialise

Lifecore Biomedical's last stock rating was published by Craig-Hallum on Nov 22, 2024. The company gave LFCR a "Buy" rating, the same as its previous rate.

Lifecore Biomedical Financial Forecast

Lifecore Biomedical Revenue Forecast

May 27Feb 27Nov 26Aug 26May 26Feb 26Nov 25Aug 25May 25Feb 25Nov 24Aug 24May 24Feb 24Nov 23Aug 23May 23Feb 23Nov 22Aug 22May 22Feb 22Nov 21Aug 21May 21Feb 21Nov 20Aug 20May 20Feb 20
Revenue----------------$31.55M$27.60M$38.80M$43.35M$47.63M$53.07M$129.49M$53.07M$139.83M$135.64M$130.90M$137.78M$156.13M$138.71M
Avg Forecast$45.60M$42.91M$37.67M$32.85M$41.92M$37.82M$32.55M$27.08M$39.36M$34.74M$29.75M$23.19M$35.02M$35.77M$30.24M$24.54M$29.05M$28.00M$43.00M$42.74M$45.86M$48.41M$131.68M$129.12M$124.58M$135.46M$134.37M$127.38M$155.99M$148.67M
High Forecast$46.79M$44.03M$38.66M$33.70M$43.02M$38.80M$33.39M$27.78M$40.38M$35.64M$30.52M$23.79M$35.09M$36.70M$31.03M$24.66M$29.80M$28.73M$43.83M$43.37M$46.54M$49.14M$133.65M$131.04M$126.44M$137.48M$136.37M$129.28M$158.32M$150.89M
Low Forecast$44.23M$41.61M$36.53M$31.85M$40.66M$36.67M$31.56M$26.26M$38.17M$33.69M$28.85M$22.49M$34.94M$34.69M$29.33M$24.42M$28.17M$27.15M$42.06M$42.02M$45.08M$47.60M$129.46M$126.94M$122.47M$133.17M$132.10M$125.23M$153.36M$146.16M
# Analysts111111111221111211111111111111
Surprise %----------------1.09%0.99%0.90%1.01%1.04%1.10%0.98%0.41%1.12%1.00%0.97%1.08%1.00%0.93%

Lifecore Biomedical's average Quarter revenue forecast for Aug 23 based on 2 analysts is $24.54M, with a low forecast of $24.42M, and a high forecast of $24.66M. LFCR's average Quarter revenue forecast represents a -22.20% decrease compared to the company's last Quarter revenue of $31.55M (May 23).

Lifecore Biomedical EBITDA Forecast

May 27Feb 27Nov 26Aug 26May 26Feb 26Nov 25Aug 25May 25Feb 25Nov 24Aug 24May 24Feb 24Nov 23Aug 23May 23Feb 23Nov 22Aug 22May 22Feb 22Nov 21Aug 21May 21Feb 21Nov 20Aug 20May 20Feb 20
# Analysts111111111221111211111111111111
EBITDA----------------$-2.60M$-3.75M$-3.88M$-2.27M$-3.30M$6.12M$2.44M$6.12M$11.21M$1.02M$-5.09M$5.86M$3.78M$148.00K
Avg Forecast$-442.09K$-415.98K$-365.21K$-318.42K$-406.43K$-366.61K$-315.51K$-262.51K$-381.54K$-336.75K$-288.38K$-224.79K$-339.45K$-346.75K$-293.19K$-237.92K$-281.59K$-271.42K$-416.86K$133.24K$142.96K$150.93K$410.53K$402.53K$388.38K$422.29K$418.91K$397.12K$486.32K$463.49K
High Forecast$-428.73K$-403.42K$-354.18K$-308.80K$-394.14K$-355.53K$-305.98K$-254.57K$-370.01K$-326.58K$-279.66K$-218.00K$-338.74K$-336.27K$-284.34K$-236.75K$-273.08K$-263.22K$-407.77K$135.22K$145.09K$153.18K$416.65K$408.54K$394.17K$428.59K$425.15K$403.04K$493.57K$470.40K
Low Forecast$-453.62K$-426.83K$-374.74K$-326.72K$-417.02K$-376.17K$-323.74K$-269.35K$-391.48K$-345.53K$-295.89K$-230.65K$-340.15K$-355.79K$-300.84K$-239.09K$-288.93K$-278.50K$-424.92K$130.99K$140.54K$148.38K$403.59K$395.73K$381.82K$415.16K$411.83K$390.41K$478.11K$455.65K
Surprise %----------------9.23%13.81%9.30%-17.01%-23.09%40.53%5.95%15.20%28.86%2.43%-12.16%14.77%7.78%0.32%

1 analysts predict LFCR's average Quarter EBITDA for May 22 to be $142.96K, with a high of $145.09K and a low of $140.54K. This is -97.66% lower than Lifecore Biomedical's previous annual EBITDA (Feb 22) of $6.12M.

Lifecore Biomedical Net Income Forecast

May 27Feb 27Nov 26Aug 26May 26Feb 26Nov 25Aug 25May 25Feb 25Nov 24Aug 24May 24Feb 24Nov 23Aug 23May 23Feb 23Nov 22Aug 22May 22Feb 22Nov 21Aug 21May 21Feb 21Nov 20Aug 20May 20Feb 20
# Analysts111111111221111211111111111111
Net Income----------------$-36.13M$-15.46M$-12.45M$-12.06M$-35.88M$-7.11M$-38.44M$-7.11M$-2.87M$-11.00M$-13.30M$-5.50M$-15.15M$-4.78M
Avg Forecast$-2.16M$-4.63M$-6.79M$-10.18M$205.72K$-4.11M$-6.27M$-9.77M$102.84K$-4.53M$-8.95M$-15.02M$-3.70M$-1.85M$-6.48M$-12.03M$-13.73M$-5.55M$-6.48M$-5.40M$-848.53K$308.56K$-2.39M$-4.57M$-493.69K$668.55K$257.12K$-4.06M$-17.18M$359.99K
High Forecast$-2.08M$-4.45M$-6.52M$-9.78M$212.69K$-3.95M$-6.03M$-9.39M$106.33K$-4.35M$-8.60M$-14.43M$-3.56M$-1.78M$-6.23M$-6.02M$-13.19M$-5.34M$-6.30M$-5.28M$-829.89K$314.54K$-2.34M$-4.47M$-482.85K$681.51K$262.10K$-3.97M$-16.80M$366.97K
Low Forecast$-2.23M$-4.79M$-7.02M$-10.53M$197.63K$-4.25M$-6.49M$-10.10M$98.80K$-4.68M$-9.25M$-15.53M$-3.83M$-1.91M$-6.70M$-18.05M$-14.20M$-5.74M$-6.64M$-5.50M$-864.98K$301.78K$-2.44M$-4.66M$-503.26K$653.87K$251.47K$-4.14M$-17.51M$352.09K
Surprise %----------------2.63%2.78%1.92%2.23%42.29%-23.03%16.08%1.56%5.81%-16.45%-51.73%1.35%0.88%-13.29%

Lifecore Biomedical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LFCR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Lifecore Biomedical SG&A Forecast

May 27Feb 27Nov 26Aug 26May 26Feb 26Nov 25Aug 25May 25Feb 25Nov 24Aug 24May 24Feb 24Nov 23Aug 23May 23Feb 23Nov 22Aug 22May 22Feb 22Nov 21Aug 21May 21Feb 21Nov 20Aug 20May 20Feb 20
# Analysts111111111221111211111111111111
SG&A----------------$11.69M$10.97M$10.77M$10.88M$15.42M$9.72M$13.84M$9.72M$16.14M$17.90M$16.11M$15.22M$18.19M$16.89M
Avg Forecast$10.98M$10.33M$9.07M$7.91M$10.09M$9.11M$7.84M$6.52M$9.48M$8.36M$7.16M$5.58M$8.43M$8.61M$7.28M$5.91M$6.99M$6.74M$10.35M$10.29M$11.04M$11.66M$31.71M$31.09M$30.00M$32.61M$32.35M$30.67M$37.56M$35.80M
High Forecast$11.27M$10.60M$9.31M$8.11M$10.36M$9.34M$8.04M$6.69M$9.72M$8.58M$7.35M$5.73M$8.45M$8.84M$7.47M$5.94M$7.18M$6.92M$10.55M$10.44M$11.21M$11.83M$32.18M$31.55M$30.44M$33.10M$32.84M$31.13M$38.12M$36.33M
Low Forecast$10.65M$10.02M$8.80M$7.67M$9.79M$8.83M$7.60M$6.32M$9.19M$8.11M$6.95M$5.41M$8.41M$8.35M$7.06M$5.88M$6.78M$6.54M$10.13M$10.12M$10.85M$11.46M$31.17M$30.56M$29.49M$32.06M$31.81M$30.15M$36.93M$35.19M
Surprise %----------------1.67%1.63%1.04%1.06%1.40%0.83%0.44%0.31%0.54%0.55%0.50%0.50%0.48%0.47%

Lifecore Biomedical's average Quarter SG&A projection for Aug 23 is $5.91M, based on 2 Wall Street analysts, with a range of $5.88M to $5.94M. The forecast indicates a -49.43% fall compared to LFCR last annual SG&A of $11.69M (May 23).

Lifecore Biomedical EPS Forecast

May 27Feb 27Nov 26Aug 26May 26Feb 26Nov 25Aug 25May 25Feb 25Nov 24Aug 24May 24Feb 24Nov 23Aug 23May 23Feb 23Nov 22Aug 22May 22Feb 22Nov 21Aug 21May 21Feb 21Nov 20Aug 20May 20Feb 20
# Analysts111111111221111211111111111111
EPS----------------$-1.19$-0.51$-0.41$-0.41$-1.22$-0.24$-1.30$-0.24$-0.10$-0.38$-0.45$-0.19$-0.52$-0.16
Avg Forecast$-0.07$-0.15$-0.22$-0.33$0.01$-0.13$-0.20$-0.32-$-0.15$-0.29$-0.49$-0.12$-0.06$-0.21$-0.39$-0.45$-0.18$-0.21$-0.17$-0.03$0.01$-0.08$-0.15$-0.02$0.02$0.01$-0.13$-0.56$0.01
High Forecast$-0.07$-0.14$-0.21$-0.32$0.01$-0.13$-0.20$-0.30-$-0.14$-0.28$-0.47$-0.12$-0.06$-0.20$-0.20$-0.43$-0.17$-0.20$-0.17$-0.03$0.01$-0.08$-0.14$-0.02$0.02$0.01$-0.13$-0.54$0.01
Low Forecast$-0.07$-0.16$-0.23$-0.34$0.01$-0.14$-0.21$-0.33-$-0.15$-0.30$-0.50$-0.12$-0.06$-0.22$-0.58$-0.46$-0.19$-0.22$-0.18$-0.03$0.01$-0.08$-0.15$-0.02$0.02$0.01$-0.13$-0.57$0.01
Surprise %----------------2.67%2.83%1.95%2.34%44.36%-24.00%16.77%1.62%6.11%-17.54%-54.00%1.44%0.93%-13.71%

According to undefined Wall Street analysts, Lifecore Biomedical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LFCR previous annual EPS of $NaN (undefined).

Lifecore Biomedical Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KMDAKamada$5.75$20.00247.83%
IRWDIronwood Pharmaceuticals$3.53$8.50140.79%Buy
TLRYTilray Brands$1.24$2.2581.45%Hold
CTLTCatalent$63.48$63.500.03%Hold
LFCRLifecore Biomedical$7.47$6.50-12.99%Buy

LFCR Forecast FAQ

Is Lifecore Biomedical a good buy?

Yes, according to 2 Wall Street analysts, Lifecore Biomedical (LFCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of LFCR's total ratings.

What is LFCR's price target?

Lifecore Biomedical (LFCR) average price target is $6.5 with a range of $5 to $8, implying a -10.22% from its last price of $7.24. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Lifecore Biomedical stock go up soon?

According to Wall Street analysts' prediction for LFCR stock, the company can go down by -10.22% (from the last price of $7.24 to the average price target of $6.5), up by 10.50% based on the highest stock price target, and down by -30.94% based on the lowest stock price target.

Can Lifecore Biomedical stock reach $11?

LFCR's average twelve months analyst stock price target of $6.5 does not support the claim that Lifecore Biomedical can reach $11 in the near future.

What are Lifecore Biomedical's analysts' financial forecasts?

Lifecore Biomedical's analysts financial forecasts for the fiscal year (May 2026) are as follows: average revenue is $139.37M (high $143M, low $135.15M), average EBITDA is $-1.351M (high $-1.31M, low $-1.386M), average net income is $-19.953M (high $-19.154M, low $-20.644M), average SG&A $33.56M (high $34.43M, low $32.54M), and average EPS is $-0.647 (high $-0.621, low $-0.669). LFCR's analysts financial forecasts for the fiscal year (May 2027) are as follows: average revenue is $159.03M (high $163.18M, low $154.23M), average EBITDA is $-1.542M (high $-1.495M, low $-1.582M), average net income is $-23.759M (high $-22.826M, low $-24.564M), average SG&A $38.29M (high $39.29M, low $37.13M), and average EPS is $-0.77 (high $-0.74, low $-0.796).

Did the LFCR's actual financial results beat the analysts' financial forecasts?

Based on Lifecore Biomedical's last annual report (May 2023), the company's revenue was $103.27M, which missed the average analysts forecast of $142.78M by -27.67%. Apple's EBITDA was $-11.119M, beating the average prediction of $-837K by 1229.02%. The company's net income was $-102M, beating the average estimation of $-31.164M by 227.91%. Apple's SG&A was $43.02M, beating the average forecast of $34.38M by 25.13%. Lastly, the company's EPS was $-3.41, beating the average prediction of $-1.01 by 237.62%. In terms of the last quarterly report (May 2023), Lifecore Biomedical's revenue was $31.55M, beating the average analysts' forecast of $29.05M by 8.60%. The company's EBITDA was $-2.598M, beating the average prediction of $-282K by 822.61%. Lifecore Biomedical's net income was $-36.13M, beating the average estimation of $-13.731M by 163.13%. The company's SG&A was $11.69M, beating the average forecast of $6.99M by 67.09%. Lastly, the company's EPS was $-1.19, beating the average prediction of $-0.445 by 167.42%